



OpGen Regains Compliance With Nasdaq Listing Requirements

February 5, 2018

GAITHERSBURG, Md., Feb. 05, 2018 (GLOBE NEWSWIRE) -- **OpGen, Inc.** (NASDAQ:OPGN) announces that it has received notification from Nasdaq that the minimum bid price deficiency of the Company's stock has been cured, and it will continue to be listed and traded on The Nasdaq Stock Market. In addition, the Company has been informed that it is in compliance with all applicable listing standards of The Nasdaq Capital Market and that therefore its hearing before the Nasdaq Hearings Panel, which had been scheduled for February 8th, has been cancelled.

About OpGen

OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment.

OpGen, and Acuitas are registered trademarks of OpGen, Inc.

OpGen Contact:

Michael Farmer
Director, Marketing
240-813-1284
mfarmer@opgen.com
InvestorRelations@opgen.com

Investor Contact:

LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com
or
Bruce Voss
310-691-7100
bvoss@lhai.com



OpGen, Inc.